Hecht Beth 4
4 · Xeris Biopharma Holdings, Inc. · Filed May 1, 2026
Research Summary
AI-generated summary of this filing
Xeris (XERS) Chief Legal Officer Beth Hecht Sells 16,667 Shares
What Happened
- Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma (XERS), sold 16,667 shares on 2026-05-01. The weighted-average price was $6.23 per share, resulting in proceeds of approximately $103,805. This was a sale (code S), not a purchase.
Key Details
- Transaction date: 2026-05-01.
- Price: weighted average $6.23; individual sales ranged from $6.10 to $6.32 (report notes multiple transactions).
- Shares sold: 16,667; proceeds ≈ $103,805.
- Shares owned after transaction: not disclosed in the information provided in this summary.
- Footnotes: Transaction executed under a Rule 10b5-1 trading plan (prearranged plan). The filer can provide a breakdown of shares sold at each price within the reported range on request.
- Filing timeliness: Report filed same day (no late-filing indication in this record).
Context
- Sales made pursuant to a 10b5-1 plan are typically pre-scheduled and can be routine; they do not necessarily reflect the insider’s current view of the company’s prospects. For retail investors, purchases usually carry more direct informational value than routine insider sales.
Insider Transaction Report
Form 4
Hecht Beth
See Remarks
Transactions
- Sale
Common Stock
[F1][F2]2026-05-01$6.23/sh−16,667$103,805→ 1,193,173 total
Footnotes (2)
- [F1]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.100 to $6.320, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Signature
/s/ Beth Hecht|2026-05-01